Enveda Therapeutics, a 'Three-No' AI Biotech, Secures $130M Series C Funding and Advances Lead Candidate into Clinical Trials

Recently, AI pharmaceutical companiesEnveda TherapeuticsAnnounced that the company has completed a $130 million Series C financing round.

This round of financing was led by Kinnevik and FPV, with participation from new and existing investors including Baillie Gifford, Premji Invest, Lingotto Innovation, Lux Capital, Dimension Capital, True Ventures, and Cresset Partners.

In fact, from the founding background of Enveda, it can be called a "three-no company" in AI pharmaceuticals: no renowned professors, no intellectual property (IP), and no core technology. It even had only $225,000 in startup funds.

But against the backdrop of a cooling AI + biopharmaceuticals track, Enveda has maintained a very good financing rhythm.

In 2023, the company secured over $100 million in Series B1 financing, and in June this year, it received an additional $55 million in Series B2 financing.

As of now, Enveda'sThe total financing amount has reached 360 million US dollars.

"Grassroots Team"

Compared with some AI pharmaceutical star companies at present, Enveda's founding background is actually not outstanding.

FounderViswa ColluruNeither a university professor, nor initially favored by venture capital funds, nor a seasoned industry expert, in the vast crowd of biopharmaceutical entrepreneurs filled with influential figures, it indeed seems less impressive.

However, he once served as the product manager of Recursion Pharmaceuticals.

Recursion is one of the earliest AI pharmaceutical companies to go public globally, garnering significant market attention. It leverages machine learning, high-throughput cell imaging, and measurement to transform the phenotypic screening process for new drug discovery.

Viswa Colluru's experience as a product manager at Recursion taught him to integrate computational processes with drug development, but he has a preference for using natural active substances in drug discovery.

Viswa Colluru believes that people nowadays have overlooked the chemical space of natural products and their derivatives. Natural products are usually heavier than synthetic ones, containing more oxygen and less nitrogen, although they violate many rules used for small molecule drugs.Chemical rules, but still able to become a drug.

Therefore,Viswa ColluruThe core idea is to reinvigorate the pharmaceutical industry's focus on natural product discovery, as many of the world's greatest drugs are derived from nature.

In order to advance this mission,Viswa Colluru wants to start aEnveda Biosciences, Inc., leveraging large-scale metabolomics and artificial intelligence to significantly accelerate the discovery process of natural products.

ButDue to his unremarkable background, Viswa Colluru could only choose to start his own business. At the time, he only had a work visa in the United States, but he still proceeded without hesitation.Invest all their savings into it.

With a little funding from Recursion's former chief security officer, a total of $225,000 launched the entrepreneurial journey.

Figure: Viswa Colluru

To save money, he could only return to his homeland, India, where he built a team and validated the platform while taking advantage of the low labor and rental costs.

To this day,The executive team of Enveda also has few members with exceptionally impressive backgrounds., such as the industry-valued work experience in multinational pharmaceutical companies, while more middle and senior positions come from small biotech companies.CompanyBoth the Chief Technology Officer and the Chief Product Officer areReSenior staff of Cursion.

FirstPipeline enters clinical stage

Founder Viswa Colluru said, "We developed our platform to rapidly expand access to natural chemistry, obtaining drug candidates at about four times the speed."

The company's core platform is PRISM, trained on over 1 billion unlabeled mass spectrometry data.It is not only the first foundational model specifically designed for natural chemistry but also the world's largest searchable library of natural products.

Enveda Through Core Sampling Technology IsLiquid Chromatography-Tandem Mass Spectrometry(LC-MS/MS) technology, collecting natural active substances in plants.

Enveda claims to have establishedThe World's Largest Plant-Based Natural Molecular Sample Library, linking 38,000 plants to 12,000 human diseases and symptoms.

By analyzing the database, the drug with the highest therapeutic potential is identified, and then through deep learning, Enveda can directly predict chemical structures based on raw measurement data.

Enveda also builds high-throughput screening processes to conduct in vitro and in vivo tests on compounds in its chemical library. These subsequent empirical measurements help quickly assess critical drug properties, such as their functional characteristics and ultimate distribution in the body.

The company's first pipeline has entered the clinical stage.ENV-294 is a first-in-class oral small molecule drug for the treatment of atopic dermatitis, which has entered Phase 1 clinical trials, with the first patient dosed in late October.

Figure: Part of Enveda's pipeline

In addition, the company will also advance its deep pipeline of 10 development candidates and multiple discovery projects, with expectations to obtain INDs and enter clinical trials between 2025 and 2026.

Recommended Reading